Release date: 2017-07-18
With the continuous advancement of tumor-targeted therapy and personalized therapy, more and more doctors are aware of the importance of genome sequencing of tumors. From the tumor genome analysis, more targeted and more effective targeted treatments can often be found to bring better curative effect to patients. However, quickly finding potential treatment options from large amounts of genomic data is not an easy task, but it is where computer and artificial intelligence programs can make a difference.
Recently, IBM and the New York Genomics Center collaborated to publish a study in which the Watson AI system of IBM obtained the same results as a group of experts by analyzing the genomic data of a brain tumor patient in much less time. The study was published in the recent issue of Neurology Genetics.
This exploratory study was conducted in a patient with glioblastoma. Glioblastoma is a very dangerous cancer with a high mortality rate and an average survival time of less than 15 months after diagnosis. For such cancer patients, time is extremely valuable, and the sooner a targeted treatment is found, the more likely it is to extend the life of the patient.
As early as 2014, IBM collaborated with the New York Genomics Center to develop a program for analyzing tumor genomes based on IBM's Watson Artificial Intelligence System, called Watson's genome analysis. The team tried the beta version of the program on this patient. It can find targeted treatments for specific genetic changes from more than 27 million biomedical papers.
The researchers obtained a biopsy sample of the tumor and a blood sample from the patient, and sequenced the DNA in the two samples and the RNA in the tumor. For comparison, these sequencing data were sent to the IBM Watson Genome Program and a team of bioinformatics and oncologists for analysis. The Watson system completed a report of clinical treatment options for consideration in just 10 minutes, and the expert analysis took 160 hours to get a similar report. The Watson system has even found more genetic mutations that may be targeted for treatment than the expert group.
Dr. Robert Darnell, co-author of the study, founder and director of the New York Genome Center, and Professor Rockefeller University, said: "Our collaboration explores cutting-edge challenges and opportunities for using genomics to help cancer patients. We offer two key questions. Preliminary perspective: What clinical value can be extracted from different commercial or research cancer genome platforms, and how to consider the use of this value."
Vanessa Michelini, an innovation leader in the Watson Genome Program, said: "This study demonstrates the potential of the Watson Genome Program to help doctors expand the use of precision tumor treatment programs. The leading researcher in cancer genomics is applying precision medicine to Great progress has been made in cancer patients, but analyzing genomic data is still a big obstacle, and that is where Watson can help."
This research is part of the effort by the New York Genomics Center to advance the use of next-generation sequencing technology in precision medicine. To further validate and improve the Watson genome program, the New York Genomics Center is conducting a larger-scale glioblastoma trial and another trial involving up to 200 patients with various cancers.
We hope that this program will be widely used as soon as possible to bring accurate treatment to more cancer patients.
Source: Bio Valley
Macadamia Nuts And Kernels,Macadamia Nuts,Macadamia Kernels,Macadamia Nuts Kernels
Weishan Yuanxing Walnuts Co.,Ltd. , https://www.walnutsxxy.com